Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | Al |
| Molecular Weight | 26.9815 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 3 |
SHOW SMILES / InChI
SMILES
[Al+3]
InChI
InChIKey=REDXJYDRNCIFBQ-UHFFFAOYSA-N
InChI=1S/Al/q+3
DescriptionCurator's Comment: Description was created based on several sources, including
https://www.google.com/patents/US2824042 | https://www.ncbi.nlm.nih.gov/pubmed/22718290 | https://www.ncbi.nlm.nih.gov/pubmed/15516810 | https://www.ncbi.nlm.nih.gov/pubmed/10211213 | https://www.drugs.com/monograph/aluminum-acetate.html
Curator's Comment: Description was created based on several sources, including
https://www.google.com/patents/US2824042 | https://www.ncbi.nlm.nih.gov/pubmed/22718290 | https://www.ncbi.nlm.nih.gov/pubmed/15516810 | https://www.ncbi.nlm.nih.gov/pubmed/10211213 | https://www.drugs.com/monograph/aluminum-acetate.html
Burow invented an astringent antiseptic solution of aluminium acetate in water to relieve the itching and inflammation of minor skin irritations. At present the oflicial U. S. P. procedure to made Burow's solution involves the reaction of aluminum sulfate, calcium carbonate and acetic acid to form aluminum sub-acetate, also termed basic aluminum acetate.
The solution is available as an over-the-counter drug for topical administration, with brand names including Domeboro. Burow's solution has been shown to be effective against chronic suppurative otitis media and otitis externa. It is active against bacteria resulting in damage to the cell wall.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL2364031 |
|||
Target ID: GO:0042310 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | DOMEBORO Approved UseTemporarily relieves minor skin irritations due to:
– Poison ivy | – Poison oak
– Poison sumac | – Insect bites
– Athlete’s foot | – Rashes caused by soaps, detergents, cosmetics, or jewelry |
|||
| Curative | DOMEBORO Approved UseThis medication is used to treat an outer ear infection (external otitis). This product contains acetic acid/aluminum acetate, a combination that stops the growth of bacteria and fungus. Treating the infection reduces pain and swelling in the ear. Wetness in the ear canal can help bacteria and fungus to grow. This medication also causes drying of the ear canal, helping to cure the infection. |
PubMed
| Title | Date | PubMed |
|---|---|---|
| The ineffectiveness of aluminum subacetate in rheumatoid arthritis. | 1948 Apr 8 |
|
| Aluminum fluoride induces phosphatidylinositol turnover, elevation of cytoplasmic free calcium, and phosphorylation of the T cell antigen receptor in murine T cells. | 1987 Nov 15 |
|
| Cardiovascular manifestations of aluminium phosphide intoxication. | 1989 Sep |
|
| Aluminum fluoride inhibition of glucocorticoid receptor inactivation and transformation. | 1990 Apr 10 |
|
| Plasma renin activity in shock due to aluminium phosphide poisoning. | 1990 Jun |
|
| Hypermagnesemia following aluminum phosphide poisoning. | 1991 Feb |
|
| Requirement for intramolecular domain interaction in activation of G protein alpha subunit by aluminum fluoride and GDP but not by GTP gamma S. | 1994 Nov 25 |
|
| Manipulation of B cell antigen receptor tyrosine phosphorylation using aluminum fluoride and sodium orthovanadate. | 1995 Nov |
|
| Effect of aluminum phosphide on blood glucose level. | 1999 Feb |
|
| Effects of trace metal compounds on HIV-1 reverse transcriptase: an in vitro study. | 1999 May |
|
| Intravascular hemolysis in aluminium phosphide poisoning. | 1999 Sep |
|
| Effect of N-acetylcysteine and L-NAME on aluminium phosphide induced cardiovascular toxicity in rats. | 2001 Apr |
|
| Cholinesterase inhibition by aluminium phosphide poisoning in rats and effects of atropine and pralidoxime chloride. | 2001 Jan |
|
| Fluoride plus aluminum: useful tools in laboratory investigations, but messengers of false information. | 2002 |
|
| Aluminum as a toxicant. | 2002 Aug |
|
| Bone cell mitogenic action of fluoroaluminate and aluminum fluoride but not that of sodium fluoride involves upregulation of the insulin-like growth factor system. | 2002 May |
|
| Final report on the safety assessment of aluminum silicate, calcium silicate, magnesium aluminum silicate, magnesium silicate, magnesium trisilicate, sodium magnesium silicate, zirconium silicate, attapulgite, bentonite, Fuller's earth, hectorite, kaolin, lithium magnesium silicate, lithium magnesium sodium silicate, montmorillonite, pyrophyllite, and zeolite. | 2003 |
|
| Aluminum inclusion macrophagic myofasciitis: a recently identified condition. | 2003 Nov |
|
| The role of metals in neurodegenerative processes: aluminum, manganese, and zinc. | 2003 Nov 15 |
|
| Parenteral nutrition-associated cholestasis in neonates: the role of aluminum. | 2003 Sep |
|
| Intracellular mechanisms underlying aluminum-induced apoptosis in rabbit brain. | 2003 Sep 15 |
|
| The giant protein HERC1 is recruited to aluminum fluoride-induced actin-rich surface protrusions in HeLa cells. | 2004 Feb 13 |
|
| [Pharmaceutical and pharmacological evaluation of Burow's solution (aluminum acetate solution), hospital preparation, and development of its rapid preparation method]. | 2004 Nov |
|
| Aluminum: new recognition of an old problem. | 2005 Dec |
|
| Effects of aluminum on the nervous system and its possible link with neurodegenerative diseases. | 2005 Nov |
|
| Cytochrome-c oxidase inhibition in 26 aluminum phosphide poisoned patients. | 2006 |
|
| Aluminum and Alzheimer's disease, a personal perspective after 25 years. | 2006 |
|
| Some aspects of astroglial functions and aluminum implications for neurodegeneration. | 2006 Aug 30 |
|
| An effector domain mutant of Arf6 implicates phospholipase D in endosomal membrane recycling. | 2006 Jan |
|
| Aluminum and other metals in Alzheimer's disease: a review of potential therapy with chelating agents. | 2006 Nov |
|
| Blood-brain barrier flux of aluminum, manganese, iron and other metals suspected to contribute to metal-induced neurodegeneration. | 2006 Nov |
|
| Aluminum and Alzheimer's disease: a new look. | 2006 Nov |
|
| The role of aluminum and copper on neuroinflammation and Alzheimer's disease. | 2006 Nov |
|
| Mechanisms of aluminum-induced neurodegeneration in animals: Implications for Alzheimer's disease. | 2006 Nov |
|
| Ototoxic effect of Burow solution applied to the guinea pig middle ear. | 2007 Aug |
|
| Neurological adverse events of immunization: experience with an aluminum adjuvanted meningococcal B outer membrane vesicle vaccine. | 2007 Oct |
|
| Relationship between physical and chemical properties of aluminum-containing adjuvants and immunopotentiation. | 2007 Oct |
|
| Reversible myocardial injury associated with aluminum phosphide poisoning. | 2007 Sep |
|
| Ablative laser resurfacing: high-energy pulsed carbon dioxide and erbium:yttrium-aluminum-garnet. | 2007 Sep-Oct |
|
| Hyperglycemia in acute aluminum phosphide poisoning as a potential prognostic factor. | 2008 Jul |
|
| Aluminum phosphide fatalities at mild exertion in asymptomatic children: a clue to understand the variations of the autopsy findings. | 2009 Aug |
|
| Retrospective analysis of 4-week inhalation studies in rats with focus on fate and pulmonary toxicity of two nanosized aluminum oxyhydroxides (boehmite) and pigment-grade iron oxide (magnetite): the key metric of dose is particle mass and not particle surface area. | 2009 May 17 |
|
| Altered glucose homeostasis in response to aluminium phosphide induced cellular oxygen deficit in rat. | 2010 Jul |
|
| Blood levels of methemoglobin in patients with aluminum phosphide poisoning and its correlation with patient's outcome. | 2011 Mar |
|
| Effect of acute aluminum phosphide exposure on rats: a biochemical and histological correlation. | 2012 Nov 23 |
|
| New insight into artifactual phenomena during in vitro toxicity assessment of engineered nanoparticles: study of TNF-α adsorption on alumina oxide nanoparticle. | 2013 Apr |
|
| Gene expression profile of mouse fibroblasts exposed to a biodegradable iron alloy for stents. | 2013 Nov |
|
| 1H NMR spectroscopic analysis detects metabolic disturbances in rat urine on acute exposure to heavy metal tungsten alloy based metals salt. | 2014 Mar 25 |
|
| Pesticide exposure and depression among male private pesticide applicators in the agricultural health study. | 2014 Sep |
|
| Molecular basis of carcinogenicity of tungsten alloy particles. | 2015 Mar 15 |
Sample Use Guides
DOMEBORO® SOOTHING SOAK
– dissolve 1 to 3 packets in a pint (16 oz) of cool or warm water
– stir until fully dissolved; do not strain or filter. The resulting mixture contains 0.16% (1 packet), 0.32% (2 packets), or 0.48% (3 packets) aluminum acetate and is ready for use
For use as a soak:
– soak affected area for 15 to 30 minutes as needed, or as directed by a doctor
– repeat 3 times a day or as directed by a doctor
– discard solution after each use.
For use as a compress or wet dressing:
– soak a clean, soft cloth in the solution.
– apply cloth loosely to affected area for 15 to 30 minutes
– repeat as needed or as directed by a doctor
– discard solution after each use
Route of Administration:
Topical
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C68232
Created by
admin on Fri Dec 15 16:06:14 GMT 2023 , Edited by admin on Fri Dec 15 16:06:14 GMT 2023
|
||
|
NCI_THESAURUS |
C597
Created by
admin on Fri Dec 15 16:06:14 GMT 2023 , Edited by admin on Fri Dec 15 16:06:14 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
C68233
Created by
admin on Fri Dec 15 16:06:14 GMT 2023 , Edited by admin on Fri Dec 15 16:06:14 GMT 2023
|
PRIMARY | |||
|
104727
Created by
admin on Fri Dec 15 16:06:14 GMT 2023 , Edited by admin on Fri Dec 15 16:06:14 GMT 2023
|
PRIMARY | |||
|
1546162
Created by
admin on Fri Dec 15 16:06:14 GMT 2023 , Edited by admin on Fri Dec 15 16:06:14 GMT 2023
|
PRIMARY | RxNorm | ||
|
DTXSID70912343
Created by
admin on Fri Dec 15 16:06:14 GMT 2023 , Edited by admin on Fri Dec 15 16:06:14 GMT 2023
|
PRIMARY | |||
|
DB14519
Created by
admin on Fri Dec 15 16:06:14 GMT 2023 , Edited by admin on Fri Dec 15 16:06:14 GMT 2023
|
PRIMARY | |||
|
3XHB1D032B
Created by
admin on Fri Dec 15 16:06:14 GMT 2023 , Edited by admin on Fri Dec 15 16:06:14 GMT 2023
|
PRIMARY | |||
|
60272
Created by
admin on Fri Dec 15 16:06:14 GMT 2023 , Edited by admin on Fri Dec 15 16:06:14 GMT 2023
|
PRIMARY | |||
|
30150
Created by
admin on Fri Dec 15 16:06:14 GMT 2023 , Edited by admin on Fri Dec 15 16:06:14 GMT 2023
|
PRIMARY | |||
|
3XHB1D032B
Created by
admin on Fri Dec 15 16:06:14 GMT 2023 , Edited by admin on Fri Dec 15 16:06:14 GMT 2023
|
PRIMARY | |||
|
49470
Created by
admin on Fri Dec 15 16:06:14 GMT 2023 , Edited by admin on Fri Dec 15 16:06:14 GMT 2023
|
PRIMARY | |||
|
22537-23-1
Created by
admin on Fri Dec 15 16:06:14 GMT 2023 , Edited by admin on Fri Dec 15 16:06:14 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
